These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34988452)

  • 1. Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
    Duchatel RJ; Mannan A; Woldu AS; Hawtrey T; Hindley PA; Douglas AM; Jackson ER; Findlay IJ; Germon ZP; Staudt D; Kearney PS; Smith ND; Hindley KE; Cain JE; André N; La Madrid AM; Nixon B; De Iuliis GN; Nazarian J; Irish K; Alvaro F; Eisenstat DD; Beck A; Vitanza NA; Mueller S; Morris JC; Dun MD
    Neurooncol Adv; 2021; 3(1):vdab169. PubMed ID: 34988452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
    Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
    Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
    Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
    J Neurosurg Pediatr; 2019 Jun; 23(6):719-725. PubMed ID: 30952114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
    Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ
    Front Oncol; 2019; 9():92. PubMed ID: 30873381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
    Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
    Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective.
    Perrone MG; Ruggiero A; Centonze A; Carrieri A; Ferorelli S; Scilimati A
    Curr Med Chem; 2021; 28(17):3287-3317. PubMed ID: 32767913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
    Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
    Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
    Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma.
    Argersinger DP; Rivas SR; Shah AH; Jackson S; Heiss JD
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
    Wierzbicki K; Ravi K; Franson A; Bruzek A; Cantor E; Harris M; Homan MJ; Marini BL; Kawakibi AR; Ravindran R; Teodoro R; Yadav VN; Koschmann C
    Curr Oncol Rep; 2020 Feb; 22(2):19. PubMed ID: 32030483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.